BioCentury
ARTICLE | Clinical News

Kamada's inhaled AAT meets in U.S. Phase II

August 30, 2016 7:00 AM UTC

Kamada Ltd. (Tel Aviv:KMDA; NASDAQ:KMDA) advanced $0.36 to $4.89 on NASDAQ on Tuesday after its inhaled alpha-1 antitrypsin ( AAT; A1AT; SERPINA1) met the primary endpoint in a 36-patient U.S. Phase II study to treat AAT deficiency (AATD). Patients who received 80 or 160 mg of the product twice daily for 12 weeks had a significant increase in the concentration of antigenic AAT in epithelial lining fluid vs. placebo (p<0.0005 for low-dose inhaled AAT and p<0.002 for high-dose).

Additionally, Kamada said both doses led to a significant increase vs. placebo in levels of anti-neutrophil elastase inhibitory levels (ANEC) in epithelial lining fluid. ...